Targovax ASA appoints Dr. Erik Digman Wiklund as new CEO

OSLO, Norway, Oct. 20, 2021 -- (Healthcare Sales & Marketing Network) -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces the appointment of Dr. Erik Digm... Biopharmaceuticals, Oncology, Personnel Targovax
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news